NASDAQ:CGIX - Cancer Genetics Stock Price, Forecast & News

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

Cancer Genetics Inc (NASDAQ:CGIX) announced its earnings results on Tuesday, April, 16th. The medical research company reported ($0.14) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.16) by $0.02. The medical research company earned $6.80 million during the quarter. Cancer Genetics had a negative net margin of 59.28% and a negative return on equity of 139.59%. View Cancer Genetics' Earnings History.

Cancer Genetics is scheduled to release their next quarterly earnings announcement on Tuesday, April 21st 2020. View Earnings Estimates for Cancer Genetics.

Headlines about CGIX stock have been trending positive on Wednesday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cancer Genetics earned a daily sentiment score of 2.8 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View News Stories for Cancer Genetics.

Cancer Genetics saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 28,500 shares, a decrease of 65.0% from the January 15th total of 81,400 shares. Based on an average trading volume of 664,200 shares, the short-interest ratio is currently 0.0 days. Currently, 1.5% of the shares of the company are short sold. View Cancer Genetics' Current Options Chain.

Some companies that are related to Cancer Genetics include Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI), OpGen (OPGN), First Choice Healthcare Solutions (FCHS) and Aeon Global Health (AGHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cancer Genetics investors own include Actinium Pharmaceuticals (ATNM), Activision Blizzard (ATVI), Novavax (NVAX), Ford Motor (F), Gilead Sciences (GILD), Opko Health (OPK), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), NovaBay Pharmaceuticals (NBY) and TransEnterix (TRXC).

Cancer Genetics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (8.00%), Oxford Asset Management LLP (1.12%) and Bank of Montreal Can (0.48%). Company insiders that own Cancer Genetics stock include John A Roberts, John Pappajohn and Michael Glenn Miles. View Institutional Ownership Trends for Cancer Genetics.

CGIX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Cancer Genetics.

CGIX stock was acquired by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP and Bank of Montreal Can. Company insiders that have bought Cancer Genetics stock in the last two years include John A Roberts, John Pappajohn and Michael Glenn Miles. View Insider Buying and Selling for Cancer Genetics.

Shares of CGIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CGIX stock can currently be purchased for approximately $4.29.

Cancer Genetics has a market capitalization of $9.01 million and generates $27.47 million in revenue each year. Cancer Genetics employs 150 workers across the globe.View Additional Information About Cancer Genetics.

The official website for Cancer Genetics is http://www.cancergenetics.com/.

Cancer Genetics' mailing address is 201 ROUTE 17 NORTH 2ND FLOOR, RUTHERFORD NJ, 07070. The medical research company can be reached via phone at 201-528-9200 or via email at [email protected]